153708-81-7

Basic information

• Product Name: 3-(5-(4-chlorophenyl)-1-(3-chloropyridazin-6-yl)-3-pyrazolyl]propionic acid
• Synonyms: 3-(5-(4-chlorophenyl)-1-(3-chloropyridazin-6-yl)-3-pyrazolyl]propionic acid
• CAS NO: 153708-81-7
• Molecular Weight: 363.203
• Mol File: 153708-81-7.mol

Chemical Properties

• CAS DataBase Reference: 3-(5-(4-chlorophenyl)-1-(3-chloropyridazin-6-yl)-3-pyrazolyl]propionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(5-(4-chlorophenyl)-1-(3-chloropyridazin-6-yl)-3-pyrazolyl]propionic acid(153708-81-7)
• EPA Substance Registry System: 3-(5-(4-chlorophenyl)-1-(3-chloropyridazin-6-yl)-3-pyrazolyl]propionic acid(153708-81-7)

Safety Data

• Hazardous Substances Data: 153708-81-7(Hazardous Substances Data)

Upstream product

• 99-91-2 para-chloroacetophenone 
• 856847-88-6 3-chloro-6-hydrazinylpyridazine hydrochloride 
• 111881-78-8 6-(4-chlorophenyl)-4,6-dioxohexanoic acid 

Downstream Products

• 1254703-78-0 C₁₆H₁₃ClN₄O₃ 
• 1443777-99-8 3-(5-(4-chlorophenyl)-1-(6-methoxypyridazin-3-yl)-1Hpyrazol-3-yl)-1-(piperidin-1-yl)propan-1-one 

Relevant articles and documents

Pyrazole derivatives as inhibitors of arachidonic acid-induced platelet aggregation

Antiplatelet drugs are promising therapeutics to intervene with platelet aggregation in arterial thrombosis, most prominently in myocardial infarction and ischemic stroke. Here, we describe the synthesis and structure-activity relationships of potent inhibitors of platelet aggregation based on the 1,5-diarylpyrazol-3-carboxamide scaffold. Analogs from this series demonstrated potent anti-aggregatory activities against arachidonic acid-induced platelet aggregation, as measured by turbidimetric method of Born. 1,5-Diarylpyrazole-3- carboxamides obtained with small-basic amines (7, 8, 50, 51, 61, 62) displayed the strongest activity with IC50 values in low nanomolar range (5.7-83 nM). On the basis of their high potency in cellular environment, these straightforward pyrazole derivatives may possess potential in the design of more potent compounds for intervention with cardiovascular diseases.

Synthesis of 1,5-diarylpyrazol-3-propanoic acids towards inhibition of cyclooxygenase-1/2 activity and 5-lipoxygenase-mediated LTB4 formation

A set of 25 derivatives of 3-[1-(6-substituted-pyridazin-3-yl)-5-(4- substitutedphenyl)-1H-pyrazol-3-yl]propanoic acids has been synthesized and evaluated for their in vitro cyclooxygenase-1/2 (COX-1/ 2) inhibitory activity using assays with purified COX-1 and COX-2 enzymes as well as for their 5-lipoxygenase (5-LO)-mediated LTB4 formation inhibitory activity using an assay with activated human polymorphonuclear leukocytes (PMNL). Among the synthesized compounds, especially 4g showed COX-1 (IC50 = 1.5 μM) and COX-2 (IC50 = 1.6 μM) inhibitory activity, whereas compounds 4b and 4 f resulted in the inhibition of 5-LO-mediated LTB4 formation at 14 μM and 12 μM IC50 values, respectively, without any significant inhibition on COX isoforms. ECV · Editio Cantor Verlag.

Pharmacologically active N-1 and C-5 heterocyclic pyrazoles and method for synthesizing the same

N-1 and C-5 heterocyclic pyrazoles, a method of their preparation, compositions containing the same and methods of their use are disclosed. The pyrazoles are useful in alleviating inflammatory and cardiovascular disorders in mammals.